Biological Sciences

Dr Simon Kolstoe

Senior Fellow

Biological Sciences

simon.kolstoe@port.ac.uk

Profile

Simon gained a first class BSc in Biomedical Science at the University of Southampton before joining the laboratory of Professor Steve Wood for a PhD in Biochemistry. His project involved the use of X-ray crystallography in rational drug design for the pentraxin family of proteins.

After graduating in 2005 Simon took up a post-doctoral position working for Professor Sir Mark Pepys FRS at the Centre for Amyloidosis and Acute Phase Proteins, UCL Medical School. Here his work on depleters of C-reactive protein was published on the front cover of Nature in 2006. A second project developing small molecules targeting the serum protein Transthyretin contributed towards the group being awarded one of the first Wellcome Trust Seeding Drug Discovery Initiative awards in 2007. This work was subsequently patented and licensed to GSK in 2009. In 2010 Simon was promoted to Senior Post-doctoral Research Associate in the newly founded Wolfson Drug Discovery Unit based at the Royal Free Hospital (UCL), where he continued working on similar projects this time in close collaboration with industrial partners and the NHS.

Simon joined the University of Portsmouth in April 2012 as a tenure-track Senior Fellow. He collaborates closely with his old research group although is initiating a number of new projects based upon structure led drug design. He is also interested in protein-DNA interactions and the use of mammalian cell lines for producing recombinant protein for biophysical characterisation. He is a member of the British Science Association and the Biochemical Society.

Coupled to his biomedical research Simon has a master’s degree in Research Ethics, is vice-chair of Southampton A NHS research ethics committee, and has research collaborations with the Clinical Ethics and Law group at the University of Southampton.

Publications

Recent Publications

 

More recent publications

 

  • Kolstoe S, Wood SP (2010) Serum Amyloid P component. Chapter 26, Protein Misfolding Disease: Current and emerging Principles and Therapies ed. M. Ramirez-Alvarado, J. Kelly and C. Dobson, John Wiley & Sons Inc., New Jersey.
  • Kolstoe SE, Morrison AJ, Cobb AJA, Coyne A, Gill R, Smith MD, Ley SV, Wood SP, Pepys MB (2010) Targeting transthyretin - X-ray crystallography and rational drug design. Amyloid 17(S1):102.
  • Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 440(7088):1217-21.
  • Kolstoe SE, Wood SP (2004) Perspectives for Drug Intervention in Amyloid Disease. Current Drug Targets 5(2):151-158.
  • Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417(6886):254-9.